Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 87

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 87
---
     |                  | (204,847 | ) |
| Comprehensive Loss                    |     | $                | (534,739 | ) |     | $                | (472,234 | ) |

The accompanying Notes are an integral part of these Financial Statements

<div align='center'>68</div>

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ DEFICIT

(unaudited)

| Balance September 30, 2023                  
 Common Shares issued for Cash               
 Unrealized Loss                             
 Net Income ( Loss)                          |     | Series A Preferred 
 Shares             |    409,551 |     | Amount |    40 |     | Series AA Preferred 
 Shares              | 34 |     | Amount | - |     | Series NC Preferred 
 Shares              | 15,007 |     | Amount | 2 |     | Common 
 Shares |  3,506,366 
    608,256 |     | Amount |   352 
    61 |     | Series M Preferred 
 Shares             | 29,338 |     | Amount | 3 |     | Additional Paid-in 
 in Capital         | 14,644,467 
    400,209 |   |     | Accumulated         
 Other Comprehensive 
 Income              | (204,847 | ) |     | Accumulated 
 Deficit     | (19,748,863 
 (267,386    | ) 
 ) |     | Total | (5,103,999 
    400,269 
   (204,847 
   (267,386 | ) 
 ) 
 ) |
|:--------------------------------------------|:----|:-------------------|-----------:|:----|:-------|------:|:----|:--------------------|---:|:----|:-------|:--|:----|:--------------------|-------:|:----|:-------|--:|:----|:-------|-----------:|:----|:-------|------:|:----|:-------------------|-------:|:----|:-------|--:|:----|:-------------------|-----------:|:--|:----|:--------------------|:---------|:--|:----|:------------|:------------|:--|:----|:------|-----------:|:--|
| Balance March 31, 2024                      |     |                    |    409,551 |     | $      |    40